T2 Biosystems, Inc. (TTOO)
| Market Cap | 176.71M |
| Revenue (ttm) | 18.13M |
| Net Income (ttm) | -46.80M |
| Shares Out | 121.33M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $1.14 |
| Previous Close | $1.19 |
| Change ($) | -0.06 |
| Change (%) | -4.62% |
| Day's Open | 1.18 |
| Day's Range | 1.12 - 1.19 |
| Day's Volume | 2,418,011 |
| 52-Week Range | 0.50 - 3.79 |
Which penny stocks should you know about in 2021? Take a look at these 3 The post 3 Penny Stocks That Investors Need to Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |...
T2 Biosystems (TTOO) delivered earnings and revenue surprises of 0.00% and 1.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of T2 Biosystems (NASDAQ:TTOO) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 68.18% year over year to ($0.07), which were in lin...
Speeds Up Development of T2Biothreat, T2Resistance, Comprehensive Sepsis Panel, Next-Generation Instrument Speeds Up Development of T2Biothreat, T2Resistance, Comprehensive Sepsis Panel, Next-Generation...
With penny stocks, knowing the most popular industries can make your watchlist competitive with the best traders out there The post Penny Stocks to Buy; The Most Popular Industries Right Now appeared fi...
LEXINGTON, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results...
Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Inf...
All proceeds from the book sale will be donated to Sepsis Alliance and Donate Life America
LEXINGTON, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to ei...
New York, New York--(Newsfile Corp. - March 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of T2 Biosystems, Inc. (NASDAQ: TTOO) concerning possible breaches of fiduciary duty....
T2 Biosystems (TTOO) delivered earnings and revenue surprises of -16.67% and 0.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Strong earnings sent both of these healthcare stocks higher after hours on Thursday.
Shares of T2 Biosystems (NASDAQ:TTOO) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 76.67% year over year to ($0.07), which were i...
LEXINGTON, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quar...
If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 penny stocks to watch are Bantec (OTCMKTS: BANT), Cielo Waste Solutions ...
LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate ...
The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.
TTOO stock is climbing on Friday after T2 Biosystems announced its Covid-19 test can detect the Brazilian strain. What should you know?
Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis
LEXINGTON, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, announced today that it issued an inducement aw...
Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG
T2 has been a huge beneficiary of the COVID-19 pandemic, as hospitals take a second look at its revolutionary diagnostic technology. A 300% revenue gain is projected by Wall Street for 2021 vs. 2019.
Investors are excited about the prospects of the company's COVID-19 diagnostic test.
BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tislelizumab. BeiG...
T2 Biosystems (TTOO) stock is on the rise Tuesday following positive news concerning testing for new strains of the novel coronavirus. The post TTOO Stock: 10 Things to Know About T2 Biosystems Today ap...
As the COVID-19 virus mutates into different variants, one small-cap diagnostics company says their test can detect the mutated strains: T2 Biosystems. T2 Biosystems soared as much as 49% in Tuesday pre...
Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.
T2 Biosystems (TTOO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their ...
A struggling diagnostics platform is benefiting from Sars-COVID-2 tailwinds. Its sars-COVID-2 test is accelerating the uptake of its diagnostic platform.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate ...
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q3 2020 Results - Earnings Call Transcript
T2 Biosystems (TTOO) delivered earnings and revenue surprises of 20.00% and 32.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of T2 Biosystems (NASDAQ:TTOO) fell 10% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 74.19% over the past year to ($0.08), which w...
Total revenues increase by 213% on record high quarterly product sales Total revenues increase by 213% on record high quarterly product sales
T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board
LEXINGTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results ...
Is (TTOO) Outperforming Other Medical Stocks This Year?
Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, and Biothreat Pathogens Advances Development of Diagnostics for Sepsis-Causing Pathogens, Antibiotic Resistance, ...
Is (TTOO) Outperforming Other Medical Stocks This Year?
Summit will raise awareness and highlight the critical role of rapid diagnostics for bloodstream infections, sepsis and the COVID-19 virus Summit will raise awareness and highlight the critical role of ...
Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients Payment Covers 65 Percent of the Average Cost of the Test Panel for Eligible Patients
The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument The T2SARS-CoV-2™ Panel runs on the FDA-cleared T2Dx® Instrument
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investi...
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q2 2020 Results - Earnings Call Transcript
Shares of T2 Biosystems (NASDAQ: TTOO) decreased 7.49% in after-market trading after the company reported Q2 results.
LEXINGTON, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the second qua...
About TTOO
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications,... [Read more...]
| Industry Diagnostics & Research | IPO Date Aug 7, 2014 |
| CEO John Sperzel | Employees 148 |
| Stock Exchange NASDAQ | Ticker Symbol TTOO |
Financial Performance
In 2020, T2 Biosystems's revenue was $18.13 million, an increase of 117.52% compared to the previous year's $8.34 million. Losses were -$46.80 million, -20.69% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for T2 Biosystems stock is "Strong Buy." The 12-month stock price forecast is 2.83, which is an increase of 149.34% from the latest price.